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Introduction
Bacterial bloodstream infection (BSI) and associated clinical sepsis is one of the major sources of mortality among hospitalized patients. 1 The delayed start of effective antimicrobial therapy may contribute to worse outcomes, not only in patients with severe sepsis or septic shock, 2 but also in patients with less severe sepsis. 3 It has been reported, in cases of bacteraemia, that the mortality rate doubles when there is a 24 h delay in the administration of appropriate antimicrobials. 4 In the first 6 h of sepsis-related hypotension, there is an average decrease in survival of 7.6% for every hour treatment is delayed. 2 Despite recent updates of definitions and clinical criteria, 5 earlier recognition and timely management of patients with sepsis remains challenging, especially in the context of multidrug resistance associated with bacterial species known by the acronym ESKAPE (i.e. Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species). 6 These species represent a significant threat to public health, 7 because BSIs caused by antibioticresistant bacteria are frequently treated inappropriately with empirical therapy. 8 In one study, vancomycin resistance was found to be the only independent predictor of delayed therapy in enterococcal BSIs. Current culture-based methods used to detect and identify the causative agents of BSI continue to be essential diagnostic tools, although they are often too slow to impact early therapy. 10 In contrast, culture-independent methods can greatly shorten the time to BSI diagnosis. 11 When combined with direct communication and integrated into antibiotic stewardship programmes, rapid identification methods may increase the timeliness of targeted therapy for patients with BSIs and possibly improve infectionrelated outcomes such as mortality. 12 Application of robust molecular diagnostic assays in laboratory practice that can provide accurate pathogen detection in whole-blood clinical samples may support direct clinical decision making and antimicrobial treatment for BSI patients. 13 The T2Dx, an automated instrument platform, uses T2 magnetic resonance (T2MR) technology to provide a 'sample-to-result' clinical diagnostic test.
14 The T2Bacteria Panel, which is performed on the T2Dx platform, has recently received CE (Conformité Européene) marking and will be commercially available as part of the 'T2Sepsis Solution' in Europe in the third quarter of 2017. The test was designed to enable multiplex detection of ESKAPE pathogens (in which Escherichia coli replaces Enterobacter species; hereafter designated as ESKAPEc pathogens), with a single wholeblood sample. Herein, we present the results of the first clinical evaluation of the performance of the research version of T2Bacteria in diagnosing bacteraemia.
Methods

Ethics
The study was approved by the Ethics Committee of our Institution (no. 17921/17), and written informed consent was obtained from the patients or relatives.
T2Bacteria Panel assay
The assay is run on a fully automated T2Dx instrument that completes all procedural steps in the T2Bacteria Panel after loading K 2 EDTA whole-blood samples, as follows: detergent lysis of blood cells; concentration of cellular debris, concentration of intact bacterial cells; lysis of bacterial cells by processing of the concentrated sample matrix with bead beating; amplification of bacterial DNA directly in concentrated sample matrix, using a thermostable polymerase (T2 Biosystems Inc.) and primer pairs each specific for E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa or E. coli (i.e. for each of the ESKAPEc bacteria); and, finally, T2MR detection of amplified products that occurs directly in concentrated sample matrix, by amplicon-induced clustering of superparamagnetic particles through the binding of attached species-specific probes. The internal control, a synthetic heterologous DNA target, is included and processed with each clinical sample to monitor the integrity of the T2Bacteria results. The T2Bacteria Panel yields a positive or negative result for each of the six detected species and internal control by means of seven separate detection channels. Separate detection channels arise from the instrument's automatic splitting of the amplified sample matrix into separate wells prior to T2MR detection. Each well contains a unique set of particles with attached probes specific for one of the six detected species or for the internal control. These wells are separately detected by T2MR to yield a positive or negative result for each of the six species and internal control, with a limit of detection established to be as low as 1 cfu/mL of whole blood, as reported previously. 14, 15 If the internal control is invalid, and in the absence of positive T2MR signals, an 'indeterminate' result is delivered from the instrument, which indicates that the sample could contain inhibitors that would interfere with bacterial DNA detection. 15 
Patient enrolment and sample collection
Our study was a prospective observational study performed in the Emergency Medicine Department, Infectious Diseases Unit and ICU of a 1200 bed tertiary-care teaching hospital in Rome, Italy, during a 3 month period in 2017. The hospital is entirely served by one clinical microbiology laboratory, which diagnoses an average of 90 BSI episodes per month. 16 All consecutive adult patients (aged 18 years) for whom a blood culture (BC) was ordered upon the clinical suspicion of BSI (i.e. presence of signs and/or symptoms of infection), subject to physician's discretion, were considered for inclusion. All patients were enrolled unless they had received antibiotic treatment with a novel investigational drug 30 days prior to the study, or the physician expected the patient to be discharged from the department/ unit on the day of evaluation, or death was deemed imminent and inevitable. BCs from the same patient were included only if they represented subsequent episodes of BSI, which were defined as the episodes (or cases) that occurred 14 or more days after the incident episode (i.e. the first BC positive for a microbial species). For each patient, a whole-blood sample for the T2Bacteria Panel assay was collected into 4 mL K 2 EDTA Vacutainer blood collection tubes following blood draws taken for BCs, using the same peripheral venepuncture sites. T2Bacteria samples were de-identified as to the patient's identifying information, delivered to the clinical microbiology laboratory, and processed immediately as they arrived. The T2Bacteria samples collected outside of the laboratory opening times (i.e. from 7:30 a.m. to 7:00 p.m., Monday to Saturday) were stored at 4 C until they could be processed. BC samples were processed in accordance with the routine laboratory practice for a period of 5-7 days, using the BacT/ALERT VIRTUO system (bioMérieux, Marcy l'Étoile, France). Positive flagged BCs were subjected to a BSI diagnostic algorithm that, starting from Gram-staining microscopy, relies on direct analysis using the MALDI-TOF MS BioTyper system (Bruker Daltonics, Bremen, Germany) and supplemented with the FilmArray Blood Culture ID panel (bioMérieux), as previously described. 17 Bacterial isolates that grew from positive BCs were identified using MALDI BioTyper and, in cases of unsuccessful identification, conventional phenotypic tests and/or sequencing of the 16S ribosomal RNA gene or the rpoB gene were performed. 17 
Data collection and analysis
Medical charts were reviewed to collect clinical data from enrolled patients. Baseline data collected upon enrolment included the following information: demographics; date and time of hospital admission; type of hospital ward; immune status (immunosuppressed/immunocompetent); major comorbid conditions; antimicrobial course prior to study enrolment; SOFA score for ICU patients; and quick SOFA (qSOFA) score [range, 0-3 points, with 1 point each for systolic hypotension (100 mm Hg), tachypnoea (22 breaths/min) or altered mentation] for non-ICU patients. 18 Clinical data collected after enrolment included: pertinent laboratory data (e.g. procalcitonin); microbiological results of BCs from secondary BSI episodes and of cultures from other sites of infection that were available within a time window of 7 days; and antimicrobial/antibiotic therapy information. All data were de-identified and securely stored to preserve anonymity and confidentiality.
Results obtained with the T2Bacteria Panel for each sample were compared with BC results. To resolve discrepancies between T2Bacteria and BC results, we constructed a 'true-infection criterion' similar to previous efforts. 19 Accordingly, T2Bacteria results were retrospectively evaluated by both a clinical microbiologist and an infectious diseases clinician, and falsepositive T2Bacteria results were determined to be actually true-positive results when the same microorganism detected only by T2Bacteria was isolated from a culture from another sample type (e.g. abdomen, urine or lower respiratory tract) reflecting the source of infection. 20 The time period of such an evaluation was 7 days from T2Bacteria sample draw. Therefore, Bacteraemia diagnosed by T2Bacteria assay JAC iv21 direct comparison of discordant results was adjudicated through BC results and the above-mentioned criterion.
Statistical analysis
Sensitivity, specificity and positive and negative predictive values were calculated for each detection channel to determine the analytical performance of the T2Bacteria Panel. The time to species identification was defined, molecularly, as the time to result of the T2Bacteria Panel or, conventionally, as the time to BC positivity plus the time to result by routine microbiological methods. The last was inclusive of both the initial Gram staining and final identification. Continuous variables were presented as means and standard deviations, and were compared using Student's t-test or the Mann-Whitney U-test, as appropriate. Categorical variables were presented as counts and percentages, and were compared using Fisher's exact test. Differences were considered to be statistically significant for P , 0.05. Statistical analyses were performed using Stata Version 10 software (StataCorp, College Station, TX, USA).
Results
Of the 144 patients enrolled in the study, 10 provided samples with an insufficient volume and 3 had samples that were damaged at the end of storage; another sample was excluded because it was a duplicate from the same patient and episode. In 4 of 144 cases, the T2Bacteria Panel yielded an indeterminate result due to either a technical error (one case) or an invalid result (three cases) (Figure 1 ). Including these samples, the validity rate for all T2Bacteria results in this study was 97.2% (140/144). Therefore, the final data analysis was performed on 140 samples from 129 patients with clinical suspicion of BSI (Figure 1 ). Table 1 shows the characteristics of the patients and samples admitted into the study.
Bacterial aetiology detected by T2Bacteria versus culture
A summary of the performance of T2Bacteria Panel and BC methods shows that 22 (15.7%) and 17 (12.1%) of the 140 cases of BSI yielded single bacterial pathogens by the molecular assay and conventional culture, respectively (Table S1 , available as Supplementary data at JAC Online). Multiple bacteria were detected in four (2.9%) cases by T2Bacteria and two (1.4%) cases by the BC method. Of the four polymicrobial BSIs detected by the T2Bacteria Panel, two were caused by E. faecium and P. aeruginosa, one by E. faecium and E. coli, and one by E. coli and K. pneumoniae. Three of these cases were positive for at least one microorganism by both methods, whereas one case was negative with the BC method. The microbial aetiology according to T2Bacteria Panel and culture for all the BSI samples is shown in Table 2 . There was only one sample positive for Candida albicans, which was detected by the BC method. Excluding the fungal pathogen, 12 of 23 (52.2%) bacterial species that grew from BCs (8 monomicrobial and 4 polymicrobial) were included in the T2Bacteria Panel. De Angelis et al.
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The remaining 11 bacteria (47.8%) isolated by culture belonged to species not included in the T2Bacteria Panel.
Overall agreement between T2Bacteria and culture
As shown in Table 3 , the overall sensitivity of T2Bacteria in comparison with the BC method ranged from 50.0% to 100.0% across the detection channels, with an aggregate sensitivity of 83.3% (95% CI 51.6%-97.9%) across all detection channels. Overall specificity of T2Bacteria in comparison with the BC method ranged from 94.8% to 100.0% across the detection channels, with an aggregate specificity of 97.6% (95% CI 96.3%-98.5%). There was a total of 10 concordantly identified microorganisms, 2 microorganisms isolated only by culture and 20 microorganisms detected only molecularly. Among the latter, seven (35.0%) microorganisms (three E. faecium, two E. coli, one P. aeruginosa and one A. baumannii) were considered true positives, according to the criterion previously specified. Thus, the overall sensitivity and specificity of T2Bacteria in comparison with this criterion were 89.5% (95% CI 66.9%-98.7%) and 98.4% (95% CI 97.3%-99.2%), respectively (Table 4) . Excluding two BSI cases that were polymicrobial only by the BC method, there was no agreement with culture in 19 (13.8%) of 138 cases, but the same microorganisms grew in 6 (4.4%) cases. Finally, there were 112 concordant negative detections, yielding a specificity of 89.5% and a negative predictive value of 98.2%.
The mean time to species identification was 5.5+1.4 h for T2Bacteria and 25.2+15.2 h for the BC method (P , 0.001). The mean time to negative result was 6.1+1.5 h for T2Bacteria and 120+0.0 h for the BC method (P , 0.001).
Additional analysis was performed on those patients who had a matched positive BC result (n " 8) or who met the criterion of true infection (n " 6) to determine appropriateness of therapy at the time of a positive T2Bacteria result. Inappropriate antimicrobial therapy was defined as any antimicrobial agent or dose that would not adequately treat the targeted pathogen. We found that 12.5% (1/8) and 66.7% (4/6) of patients were receiving inappropriate antimicrobial therapy at the time of the T2Bacteria result, and four of these patients were positive for E. faecium and the remaining one was positive for A. baumannii.
Assessment of variables potentially influencing T2Bacteria Panel performance
Subgroup analysis of the BC results showed that a previous antibiotic treatment, a SOFA or qSOFA score of 2 and a procalcitonin level of .2 ng/mL were significantly associated with culture-negative but T2Bacteria-positive cases compared with cases in which both culture and T2Bacteria results were negative [88.2% (15/17 Data were recorded separately for SOFA scores in ICU patients (n " 25) and for qSOFA scores in non-ICU patients (n " 115). Bacteraemia diagnosed by T2Bacteria assay
results showed that only a previous antibiotic treatment was significantly associated with T2Bacteria-positive but culture-negative cases compared with cases in which both culture and T2Bacteria results were positive [88.2% (15/17) versus 28.6% (2/7), P " 0.009]. Interestingly, all of seven culture-negative cases with true-positive T2Bacteria detections had .2 ng/mL procalcitonin levels.
Discussion
The goal of this study was to evaluate the research version of the T2Bacteria Panel in adult patients with suspected BSI treated in a large tertiary-care teaching hospital. Specifically, the T2MR technology 14, 21 was applied to the rapid detection of six bacterial pathogens (i.e. ESKAPEc) directly in whole blood, possibly without interference by empirical antimicrobial treatment, which remains a clinical conundrum with culture-based diagnostics. 22 We found that the T2Bacteria Panel was able to correctly identify 89.5% of patients as non-bacteraemic, with a mean time to negative result of 6 h. Approximately half of our BSI cases (11/20) were caused by bacterial species that were undetectable by the T2Bacteria Panel. As ESKAPEc pathogens are the most prevalent BSI agents, particularly in the emergency department, 23 the T2Bacteria Panel could therefore be recommended as a screening test. Similarly to PCR-based methods (e.g. the SeptiFast test), 24 the T2Bacteria Panel showed values of sensitivity and specificity that underscore its clinical utility as either a rule-in test or a rule-out test for bacteraemia.
In our study, the discordance rate between T2Bacteria and BC results was 13.8% (19/138 cases), with 20 microorganisms not isolated by BC but detected by the T2Bacteria Panel. Although this rate can include either false-negative BC or false-positive T2Bacteria results, it should be noted that culture-independent molecular methods frequently yield additional positive results in culture-negative blood samples, 22 and in some cases these results are shown to improve patient outcome when used to guide antibiotic therapy. 25 Here, post hoc analysis of the individual patients' T2Bacteria results with clinical significance were classified as matched positives according to the criterion specified in the text.
De Angelis et al.
iv24 chart data showed that 7 of 20 unmatched T2Bacteria detections were supported by data from subsequent clinical samples, showing infection of the patient by the same microbial species that was detected only by the molecular assay. Thus, many of our discordant results may represent cases of bacterial BSIs that were missed by culture in the initial paired (blood) sample. Further, we found that 66.7% of clinically infected patients missed by BC and correctly identified by T2Bacteria were being inappropriately treated at the time of the T2Bacteria result. Despite being universally considered the gold standard for bacteraemia diagnosis, BC methods are known to have suboptimal sensitivity in blood samples, having as low as a 65% sensitivity for the first blood-culture draw. [26] [27] [28] This is consistent with the significantly high rates of positive molecular tests with negative BC results reported recently in the literature, 24, 29, 30 as well as in our study. Similarly, the SeptiFast assay (a multiplex real-time PCR test that allows the detection of 25 microbial pathogens) was able to detect the causative pathogen in 14 (25%) of 56 patients with BSI, whereas BC was negative, 24 confirming the rates of culturenegative, SeptiFast-positive detections reported elsewhere. 31, 32 In our study, a significantly higher proportion of T2Bacteria-positive, BC-negative cases, later confirmed as true positives, were from patients who had previously been exposed to antibiotic treatment. This suggests culture insensitivity rather than a lack of specificity or clinical relevance by the T2MR molecular method, and is supported by the fact that BC is positive in only 50% of cases where BSI is clinically suspected. 26, 33 In contrast, a low apparent sensitivity of current molecular methods with respect to culture has been reported -approximately 50% for many technologies. 32, 34, 35 In our study, there were two blood samples with a paired positive BC (one for E. coli and one for K. pneumoniae) and T2Bacteria-negative results (Table S1 ). As blood is a complex matrix and several factors may affect microbial (DNA) detection, these findings remain unexplained.
Although no sepsis biomarker can be entirely specific for infection, procalcitonin is, among the more than 170 sepsis biomarkers proposed, a particularly good severity marker in sepsis. 36, 37 Whereas procalcitonin (value of .2 ng/mL) was, expectedly, 38 able to discriminate samples with BC-positive results from samples with BC-negative results, we showed that all seven samples with BC-negative but T2Bacteria-positive (true-positive) results displayed .2 ng/mL levels of this marker. Therefore, the combined information collected from both the T2Bacteria and procalcitonin tests may be more useful for managing patients with BSI.
This single-centre cohort study has some weaknesses. First, the BC and T2Bacteria tests were ordered by the physician in charge according to the patient's clinical presentation, and the availability of both tests was the primary inclusion criterion in this study. Therefore, the evaluation of negative predictive value of the T2Bacteria Panel would be done with higher precision among a patient population with high-risk characteristics. Second, as the pathogen coverage by the T2Bacteria Panel is restricted to only six bacteria, this assay is not intended to replace culture methods. Third, T2Bacteria cannot provide antimicrobial susceptibility information, thereby making it necessary that it is integrated into a diagnostic algorithm that includes susceptibility or resistance should patients continue to deteriorate in the presence of targeted therapy based on T2Bacteria's results. Fourth, the manufacturer provided a research version of the T2Bacteria Panel, which was refined for its commercial use in the EU and pending in the USA. This is the main reason why we did not include invalid T2Bacteria results in performance calculations to reflect the real efficacy of the test. Also, due to the limited number of bacteraemic patients who were enrolled in our study, the clinical sensitivity of the T2Bacteria Panel needs to be further assessed. Finally, the contamination rate is likely to be lower in the present study because the T2Bacteria sample was always collected after the BC sample. In the future, this issue should be addressed by randomly alternating this sequence.
In conclusion, the T2Bacteria Panel is a promising technology that permits a reliable identification of ESKAPEc pathogens directly from the patient's blood. Our data mirror those already obtained with the 'sibling' T2Candida Panel, and show that this novel technology has the potential to improve the time to species identification and detection in patients with clinically important bacteraemia. Future studies are warranted to confirm and further explore these findings.
